| Variceal bleeding: pharmacological therapy. | |
| | |
MedLine Citation:
|
PMID: 15920322 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The complications of portal hypertension are totally prevented if hepatic venous pressure gradient is decreased below 12 mm Hg. Besides, if this target is not achieved, a 20% decrease in portal pressure from baseline levels offers an almost total protection from variceal bleeding. This sets the rationale for drug therapy to reduce portal pressure in portal hypertension. Pharmacological therapy to decrease portal pressure includes vasoconstrictors to decrease portal blood inflow, vasodilators to decrease hepatic resistance, and combination therapy. Oral agents, such as beta-adrenergic blockers and organic nitrates, are used for long-term prevention of variceal bleeding, while parenteral agents, such as somatostatin (and analogues) and terlipressin, are used for the treatment of acute variceal bleeding. |
| | |
Authors:
|
Jaime Bosch; Juan G Abraldes |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Digestive diseases (Basel, Switzerland) Volume: 23 ISSN: 0257-2753 ISO Abbreviation: Dig Dis Publication Date: 2005 |
Date Detail:
|
Created Date: 2005-05-27 Completed Date: 2005-08-16 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8701186 Medline TA: Dig Dis Country: Switzerland |
Other Details:
|
Languages: eng Pagination: 18-29 Citation Subset: IM |
Copyright Information:
|
2005 S. Karger AG, Basel |
Affiliation:
|
Hepatic Hemodynamics Laboratory, Liver Unit, IMD, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain. jbosch@clinic.ub.es |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Oral Adrenergic alpha-Antagonists / therapeutic use Hemorrhage / drug therapy*, etiology* Humans Hypertension, Portal / complications*, drug therapy* Liver / blood supply Nitrates / therapeutic use Regional Blood Flow Varicose Veins / complications* Vasoconstrictor Agents / therapeutic use* Vasodilator Agents / therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Adrenergic alpha-Antagonists; 0/Nitrates; 0/Vasoconstrictor Agents; 0/Vasodilator Agents |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The role of endoscopy in portal hypertension.
Next Document: Refractory ascites.